EMA to review Raptor's RP103

EMA accepted for review an MAA from Raptor Pharmaceutical Corp. (NASDAQ:RPTP) for RP103 to treat nephropathic cystinosis. Raptor plans to submit an NDA to FDA for RP103 by the end of March. RP103 is a...